Nonsteroidal anti-inflammatory drug NS398 induces RECK expression in the animal model of prostate cancer.
- Author:
Zhen-Yu XU
1
;
Jian-Ping GAO
;
Ying-Hao SUN
;
Zheng-Yu ZHANG
;
Jing-Ping GE
;
Chuan-Liang XU
;
Lin-Hui WANG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Anti-Inflammatory Agents, Non-Steroidal; pharmacology; GPI-Linked Proteins; metabolism; Gene Expression Regulation; drug effects; Humans; Male; Matrix Metalloproteinase 9; metabolism; Mice; Mice, Nude; Nitrobenzenes; pharmacology; Sulfonamides; pharmacology; Tumor Cells, Cultured
- From: National Journal of Andrology 2010;16(12):1079-1082
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the regulatory effect of the nonsteroidal anti-inflammatory drug NS398 on the expression of the RECK gene in the animal model of prostate cancer.
METHODSNude mouse models of prostate cancer were divided into an experimental and a control group, the former fed with NS398 at 0.1 mg/g per day for 10, 20 and 30 days, while latter left without medication. All the mice were killed at 30 days, the mRNA expressions of RECK and MMP-9 in the tumor tissues measured by RT-PCR, and the protein level of RECK evaluated by Western blot.
RESULTSBoth the mRNA and protein expressions of RECK were increased, while the level of MMP-9 decreased, in an obviously time-dependent manner in the experimental group as compared with the control.
CONCLUSIONNS398 obviously inhibits the pathogenesis and metastasis of prostate cancer, which may be attributed to its induction of the expression of the RECK gene and suppression of the expression of MMP-9.
